Arno Therapeutics, Inc. HomeAbout UsPipelineInvestor RelationsContact Us
Arno Therapeutics is a biopharmaceutical company focused on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs
Arno Theraoeutics, Inc.
Recent Press Releases In the news Contact

April 19, 2016
Arno Therapeutics to Focus Clinical Developmental Activities on Advanced Prostate Cancer in First-of-its-Kind Phase II Study of Onapristone in Combination with ZYTIGA® more »

March 30, 2016
Arno Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update more »

March 21, 2016
Arno Therapeutics Advances Phase I/II Trial Evaluating Onapristone in Prostate Cancer to Phase II more »

January 13, 2016
Arno Therapeutics Completes $7.4 Million Common Stock Financing more »

November 16, 2015
Arno Therapeutics Reports Third Quarter 2015 Financial Results and Business Update more »

October 29, 2015
Arno Therapeutics Data Demonstrate AR-12 as Novel Antifungal Drug Against Common Finger and Toenail Fungus, Onychomycosis more »

October 21, 2015
Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains more »

View all Press Releases


July 16, 2015
ASCO 2015: Efficacy of Onapristone in PR-Expressing Tumors, Alexander Zukiwski, MD watch video »

July 16, 2015
ASCO 2015: Safety and PK Results From an Ongoing Phase I-II Study of ONA in Patients With PR-Expressing Cancers, Paul Cottu, MD, MSc watch video »

July 16, 2015
Arno explores new class of antimicrobial drugs more »

July 7, 2015
ASCO 2015: New data support continued onapristone and CDx development more »

April 8, 2015
Arno Therapeutics Seeks to Inhibit Cancer and Enhance Portfolios: CEO Alexander Zukiwski more »

May 23, 2014
Express Yourself: Arno, University of Minnesota pursue gene expression in hopes of developing a companion diagnostic more »

May 19, 2014
Do the Math: Ram Selvaraju on the Appeal of Biotechs in Orphan Diseases more »

May 9, 2014
Maxim: ARNI - Clinical progress on track; Onapristone in two dose escalation trials; Reiterating Buy and $6 price target more »

January 22, 2014
Maxim: ARNI - Onapristone now in clinical development; Revising estimates; Reiterating Buy and $6 price target more »

July 15, 2013
Orphan-Drug Marketing - Medical Marketing & Media (MM&M) eBook more »

July 8, 2013
APRs in CTCs - Drug Discovery News more »

June 13, 2013
Arno Therapeutics’ strategy is to develop onapristone companion diagnostics for each indication - Biopharm Insight more »

View All News


Arno Therapeutics, Inc.
200 Route 31 North
Suite 104
Flemington, NJ 08822

(862) 703-7170 Main
(908) 237-0071 Fax
info@arnothera.com